93 related articles for article (PubMed ID: 1605655)
21. [Early phase II study of Idarubicin combined with cytarabine in acute myelogenous leukemia. Idarubicin Study Group].
Ogawa M; Masaoka T; Yamada K; Kimura K
Gan To Kagaku Ryoho; 1993 May; 20(7):907-14. PubMed ID: 8489297
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
Kearns CM; Blakley RL; Santana VM; Crom WR
Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
[TBL] [Abstract][Full Text] [Related]
23. Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237.
Dreyer ZE; Kadota RP; Stewart CF; Friedman HS; Mahoney DH; Kun LE; McCluggage CW; Burger PC; Kepner J; Heideman RL;
Neuro Oncol; 2003 Oct; 5(4):261-7. PubMed ID: 14565163
[TBL] [Abstract][Full Text] [Related]
24. Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.
Eksborg S; Björkholm M; Hast R; Fagerlund E
Anticancer Drugs; 1997 Jan; 8(1):42-7. PubMed ID: 9147610
[TBL] [Abstract][Full Text] [Related]
25. Pharmacology of chronic oral daily administration of idarubicin.
Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Rimondi G; Bearz A; Stocco F; Robieux I; Boiocchi M
Haematologica; 1997; 82(5 Suppl):1-3. PubMed ID: 9402745
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic and phase I evaluation of esorubicin (4'-deoxydoxorubicin) by continuous infusion over forty-eight hours in patients with leukemia.
Kreis W; Rottach C; Budman DR; Chan K; Schulman P; Allen SL; Weiselberg L; Vinciguerra V
Cancer Res; 1988 Oct; 48(19):5580-4. PubMed ID: 3166400
[TBL] [Abstract][Full Text] [Related]
27. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte PF
Bone Marrow Transplant; 2003 Feb; 31(4):275-80. PubMed ID: 12621462
[TBL] [Abstract][Full Text] [Related]
28. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Berman E; Raymond V; Gee T; Kempin SJ; Gulati S; Andreeff M; Kolitz J; Gabrilove J; Heller G; Young CW
Semin Oncol; 1989 Feb; 16(1 Suppl 2):30-4. PubMed ID: 2928808
[No Abstract] [Full Text] [Related]
29. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
[TBL] [Abstract][Full Text] [Related]
30. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
31. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Kuffel MJ; Reid JM; Ames MM
Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
[TBL] [Abstract][Full Text] [Related]
32. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T
Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects.
Elbaek K; Ebbehøj E; Jakobsen A; Juul P; Rasmussen SN; Bastholt L; Dalmark M; Steiness E
Clin Pharmacol Ther; 1989 Jun; 45(6):627-34. PubMed ID: 2731405
[TBL] [Abstract][Full Text] [Related]
34. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
Tidefelt U; Prenkert M; Paul C
Cancer Chemother Pharmacol; 1996; 38(5):476-80. PubMed ID: 8765443
[TBL] [Abstract][Full Text] [Related]
35. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
36. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
Chiodini B; Bassan R; Barbui T
Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
[TBL] [Abstract][Full Text] [Related]
37. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
[TBL] [Abstract][Full Text] [Related]
38. Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia.
Pea F; Damiani D; Michieli M; Ermacora A; Baraldo M; Russo D; Fanin R; Baccarani M; Furlanut M
Eur J Clin Pharmacol; 1999 Jul; 55(5):361-8. PubMed ID: 10456485
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
Ueda T; Nakamura T; Ando S; Kagawa D; Sasada M; Uchino H; Johno I; Akiyama Y
Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
[TBL] [Abstract][Full Text] [Related]
40. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
Avramis VI; Weinberg KI; Sato JK; Lenarsky C; Willoughby ML; Coates TD; Ozkaynak MF; Parkman R
Cancer Res; 1989 Jan; 49(1):241-7. PubMed ID: 2908850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
